Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa J Schlein

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 2023
Parthenolide As a Therapeutic for Disseminated Canine NeoplasmsLisa J Schlein, Samuel A Brill, Rachel V Brady, et al.
Frontiers in Oncology|March 13, 2019
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain CancersLisa J Schlein, Bahaa Fadl-Alla, Holly C Pondenis, et al.
Oncotarget|November 9, 2017
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patientsAvadhut D Joshi, Rachel C Botham, Lisa J Schlein, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 2023
Parthenolide As a Therapeutic for Disseminated Canine NeoplasmsLisa J Schlein, Samuel A Brill, Rachel V Brady, et al.
Frontiers in Oncology|March 13, 2019
Immunohistochemical Characterization of Procaspase-3 Overexpression as a Druggable Target With PAC-1, a Procaspase-3 Activator, in Canine and Human Brain CancersLisa J Schlein, Bahaa Fadl-Alla, Holly C Pondenis, et al.
Oncotarget|November 9, 2017
Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patientsAvadhut D Joshi, Rachel C Botham, Lisa J Schlein, et al.
Pageof 2